Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Acalabrutinib Misses the Mark in Patients Hospitalized With COVID-19–Related Respiratory Symptoms

OncLive - November 18, 2020 - The addition of the oral BTK inhibitor acalabrutinib to best supportive care in patients with respiratory symptoms from coronavirus disease 2019 infection failed to increase the proportion of patients who remained alive and free of respiratory failure, missing the primary efficacy end points of the 2 phase 2 CALAVI trials.

Read the full article here

Related Content